Pralsetinib
from OncoPharm Hosted by John Bossaer
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 11 minutes long.
When was this OncoPharm episode published?
This episode was published on September 11, 2020.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.